Thinking on cross-border life-science deals.
Field notes, deal mechanics, and corridor intelligence from the partners who run the mandates. Written for principals weighing a transaction – not for the feed.
Signals worth a second look.
Long-form analysis on the deals shaping the Africa-Gulf-Europe-USA corridor, and the structures behind them.
-
Why the next wave of pharma value will be sourced, not invented in-house
Why leading biotechs are shifting from internal R&D to sourced innovation across borders.
-
Reading a data package the way a strategic buyer will
How to structure and present a data room so strategic acquirers move faster.
-
Structuring milestones that hold up after the deal closes
Designing earn-outs and milestones that survive integration and shifting priorities.
-
The Gulf as capital partner, not just a market
Why Gulf sovereign and family capital is becoming a strategic partner in life-science deals.
-
NewCo or sell-down: choosing the right path for a carve-out
A framework for deciding between spinning out a NewCo and selling down an asset.
-
What changed in cross-border China biotech partnering this year
The shifts in regulation and deal structure reshaping China biotech partnerships.
Pharma deal intelligence, delivered.
The cross-border deal feed.
Corridor signals, modality shifts, and the structures behind the month’s most relevant transactions – read by principals across four markets.
Every cross-border deal that mattered, in five minutes.
A tight weekly digest of licensing, M&A, and partnership activity across Africa, the Gulf, Europe, and the United States.